Closing the gap between innovation and patient impact
OMGEN was created to help rare disease and specialty care organisations overcome the barriers that prevent innovation from reaching patients — particularly in the complex and evolving gene therapy landscape.
If you are navigating challenges in strategy, access, launch, or organisational delivery, I’d welcome a focused conversation to explore how we can help.
Strategy - Rare disease commercial excellence, marketing strategy, market access, and launch planning — designed to work in the real-world environment of small populations, complex evidence, and evolving reimbursement pathways.
Consulting - Translating strategy into action — improving customer experience, embedding patient-centred planning, and aligning teams around clear vision and purpose.
Change - Building the leadership, culture, and organisational capability required to deliver — including team development, leadership, diversity, equity and inclusion, and ESG programmes.
From promise to reality- A Blueprint for change to benefit Patients
About Owen Marks
Owen Marks is Principal at OMGEN, specialising in rare disease and gene therapy commercial strategy, market access, and organisational change.
Prior to founding OMGEN, Owen was Head of Rare Diseases at Pfizer, leading a portfolio of advanced therapies across cardiology, endocrine, neuromuscular, neuropathies and haematology. He has a strong track record of securing reimbursement and navigating complex health systems, working closely with NICE, NHS England, NHS Scotland and the Department of Health and Social Care.
Owen’s career spans senior commercial and marketing roles across Europe and international markets, including leadership positions based in France and Italy, where he led rare disease and haemophilia portfolios across International developed markets and Western, Central and Eastern Europe.
He has led major organisational transformations within the pharmaceutical industry, including the integration of Global Blood Therapeutics into Pfizer, the formation of ViiV Healthcare in the UK, and planning for the Pfizer–Wyeth merger.
Alongside his commercial leadership, Owen has been a prominent voice in diversity, equity and inclusion — co-chairing Pfizer UK’s DEI group and leading initiatives recognised with a Gold award from the Employers Network for Equality and Inclusion.
He has also contributed extensively to the wider healthcare ecosystem, including chairing the ABPI Advanced Therapeutics Group and serving on the South East Board of Business in the Community.
Let’s connect
If you are working to bring innovation to patients in rare disease or gene therapy — whether shaping strategy, preparing for launch, or addressing access challenges — let’s start a conversation:
